NewsBenzingaOruka公布ORKA-001治疗斑块型银屑病的第16周2b期结果:PASI 100应答率达61%,PASI 90应答率达86%;ORKA-001有望于2027年上半年推进至3期临床试验 Oruka公布ORKA-001治疗斑块型银屑病的第16周2b期结果:PASI 100应答率达61%,PASI 90应答率达86%;ORKA-001有望于2027年上半年推进至3期临床试验 Benzinga 2026.10.26 11:13 (GMT+0) Open on Benzinga Other news Hearing Nvidia Chair Says Jensen Huang Not Coming Back Here’s How Much You Would Have Made Owning KLA Stock In The Last 20 Years Fed Minutes: 'Almost All' Officials See More Hikes, and AI Debt Is Now on the Radar Freedom Broker Maintains Buy on Euroseas, Raises Price Target to $96 Freedom Broker Maintains Buy on JD.com, Lowers Price Target to $40 Freedom Broker Maintains Buy on i-80 Gold, Lowers Price Target to $2.8